Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women

被引:8
|
作者
Lian, Jing [1 ,2 ]
Xu, En-Wei [1 ]
Xi, Yan-Feng [1 ]
Wang, Hui-Wen [1 ]
Bu, Peng [1 ]
Wang, Jin-fen [1 ]
Wang, Li-Xia [1 ]
机构
[1] Shanxi Prov Canc Hosp, Dept Pathol, Taiyuan, Shanxi, Peoples R China
[2] Shanxi Med Univ, Inst Forens Med, Taiyuan, Shanxi, Peoples R China
关键词
PIK3CA; ARMS; clinicopathologic characteristics; breast cancer; Chinese; COMPLETE RESPONSE; POOR-PROGNOSIS; PTEN; HER2; RESISTANCE; LAPATINIB; PATHWAY; RATES;
D O I
10.1177/1533033820950832
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Mutations of PIK3CA have recently been shown to play an important role in the pathogenesis and progression of breast neoplasms. The prevalence of PIK3CA in Chinese breast cancer patients may be underestimated. Therefore, we investigated the distribution of somatic PIK3CA mutation in Chinese breast cancer patients and explored their role in tumor phenotypes. Methods: Mutational analysis of PIK3CA was done in 113 primary breast cancers of Chinese women used Amplification refractory mutation system (ARMS). The relationship of PIK3CA mutations with several clinicopathologic characteristics was analyzed. Results: PIK3CA gene mutation was identified in 43(38.05%) cases and has a more significant difference between exon 9 and 20. HER2 gene amplification was 32.6% in 43 cases of PIK3CA mutation, but 37.1% in 70 cases of non-mutation (chi(2)= 0.245, P > 0.05). There was no significant correlation of the age distribution, lymph node status, histological tumor grading, ER and/or PR and P53 between 2 groups (P > 0.05). Conclusion: A high frequency of somatic PIK3CA mutation was detected in Chinese breast cancer patients, especially in exon 20. The relationship between PIK3CA gene mutation and clinical pathological features of breast cancer needs to be further studied in a large series of patients. PIK3CA mutations seem to have the potential to be used in target treatment and as an indicator of prognosis.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Analysis of PIK3CA Mutations in Breast Cancer Subtypes
    Arsenic, Ruza
    Lehmann, Annika
    Budczies, Jan
    Koch, Ines
    Prinzler, Judith
    Kleine-Tebbe, Anke
    Schewe, Christiane
    Loibl, Sibylle
    Dietel, Manfred
    Denkert, Carsten
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2014, 22 (01) : 50 - 56
  • [2] Prognosis of women with early breast cancer and PIK3CA mutations
    Di Cosimo, Serena
    Bianchi, Giulia Valeria
    Bregni, Giacomo
    de Braud, Filippo
    BREAST, 2015, 24 (03) : 283 - 284
  • [3] Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai
    Wang, Y. L.
    Dai, X.
    Li, Y. D.
    Cheng, R. X.
    Deng, B.
    Geng, X. X.
    Zhang, H. J.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04): : 14840 - 14846
  • [4] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    Cizkova, M.
    Dujaric, M-E
    Lehmann-Che, J.
    Scott, V.
    Tembo, O.
    Asselain, B.
    Pierga, J-Y
    Marty, M.
    de Cremoux, P.
    Spyratos, F.
    Bieche, I.
    BRITISH JOURNAL OF CANCER, 2013, 108 (09) : 1807 - 1809
  • [5] Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
    Chen, Li
    Yang, Liu
    Yao, Ling
    Kuang, Xia-Ying
    Zuo, Wen-Jia
    Li, Shan
    Qiao, Feng
    Liu, Yi-Rong
    Cao, Zhi-Gang
    Zhou, Shu-Ling
    Zhou, Xiao-Yan
    Yang, Wen-Tao
    Shi, Jin-Xiu
    Huang, Wei
    Hu, Xin
    Shao, Zhi-Ming
    NATURE COMMUNICATIONS, 2018, 9
  • [6] The Landscape of PIK3CA Mutations in Colorectal Cancer
    Voutsadakis, Ioannis A.
    CLINICAL COLORECTAL CANCER, 2021, 20 (03) : 201 - 215
  • [7] PIK3CA oncogenic mutations in neoadjuvant treatments for breast cancer
    Corso, Giovanni
    Veronesi, Paolo
    Intra, Mattia
    Sacchini, Virgilio
    Galimberti, Viviana
    BIOMARKERS IN MEDICINE, 2017, 11 (07) : 519 - 521
  • [8] Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer
    Harle, Alexandre
    Lion, Maeva
    Lozano, Nicolas
    Merlin, Jean-Louis
    BULLETIN DU CANCER, 2013, 100 (10) : 947 - 954
  • [9] PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data
    Zardavas, Dimitrios
    Phillips, Wayne A.
    Loi, Sherene
    BREAST CANCER RESEARCH, 2014, 16 (01):
  • [10] PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer
    Zhang, Y.
    Liu, M.
    Yang, H.
    Wang, J.
    Liu, H.
    Li, X.
    Li, J.
    Xu, J.
    Li, X.
    NEOPLASMA, 2014, 61 (04) : 461 - 467